Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL877775 | 0.84 | KMT2A (0.65) | SMN1; SMN2MAPK14RAB9ANPC1KMT2A | |
| SCHEMBL595536 | 0.82 | SMN1; SMN2 (0.69) | SMN1; SMN2RAB9ANPC1POLBKMT2A | |
| SCHEMBL12331012 | 0.81 | SMN1; SMN2 (0.67) | SMN1; SMN2MAPK14RAB9ANPC1POLB | |
| SCHEMBL243740 | 0.80 | SMN1; SMN2 (0.76) | SMN1; SMN2RAB9ANPC1POLBKMT2A | |
| SCHEMBL30602600 | 0.80 | SMN1; SMN2 (0.76) | SMN1; SMN2RAB9ANPC1POLBKMT2A | |
| SCHEMBL6629782 | 0.79 | MAPK14 (0.70) | SMN1; SMN2MAPK14RAB9ANPC1POLB | |
| SCHEMBL6431170 | 0.79 | POLB (0.48) | SMN1; SMN2MAPK14RAB9ANPC1POLB | |
| SCHEMBL27791622 | 0.79 | POLB (0.62) | SMN1; SMN2RAB9ANPC1POLBKMT2A | |
| Hydrochloric Acid SCHEMBL7607595 | 0.78 | SMN1; SMN2 (0.73) | SMN1; SMN2RAB9ANPC1POLBKMT2A | |
| SCHEMBL22861337 | 0.78 | SMN1; SMN2 (0.63) | SMN1; SMN2RAB9ANPC1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214978-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4506345-A1 | AT2R AGONIST | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company (CN) | 2025-02-12 | — | — | EP | disclosed |
| EP-4313953-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | Vicore Pharma AB (SE) | 2024-02-07 | — | — | EP | disclosed |
| CN-117242071-A | Selective angiotensin II receptor ligands | 维科尔药物公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-117222624-A | Selective angiotensin II receptor ligands | 维科尔药物公司 | 2023-12-12 | — | — | CN | disclosed |
| WO-2023193733-A1 | AT2R AGONIST | 武汉人福创新药物研发中心有限公司 | 2023-10-12 | — | — | WO | disclosed |
| WO-2022200785-A1 | SELECTIVE ANGIOTENSIN II RECEPTOR LIGANDS | VICORE PHARMA AB (SE) | 2022-09-29 | — | — | WO | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| WO-2012002502-A1 | DIHYDROPYRIMIDINONE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | 大日本住友製薬株式会社 (JP) | 2012-01-05 | — | — | WO | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| EP-2322525-A1 | Purine derivatives for use as adenosin A2A receptor agonists | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| EP-2013211-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | Novartis AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| EP-0079377-A1 | HETEROCYCLIC ALKYLENE AMIDINOUREAS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1983-05-25 | — | — | EP | disclosed |
| WO-1982004048-A1 | HETEROCYCLIC ALKYLENE AMIDINOUREAS | RORER INT OVERSEAS (US) | 1982-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | SMN1; SMN2 2150/4885MAPK14 4341/4885RAB9A 2007/4885 |
| US-20250214978-A1 | AT2R AGONIST | AGTR1, AGTR2, AVPR2 | SMN1; SMN2 3701/4885MAPK14 806/4885RAB9A 3232/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | SMN1; SMN2 2150/4885MAPK14 4341/4885RAB9A 2007/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | SMN1; SMN2 2150/4885MAPK14 4341/4885RAB9A 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.